1. Home
  2. UFPI vs BLCO Comparison

UFPI vs BLCO Comparison

Compare UFPI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UFP Industries Inc.

UFPI

UFP Industries Inc.

HOLD

Current Price

$90.47

Market Cap

5.3B

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.88

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFPI
BLCO
Founded
1955
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Forest Products
Ophthalmic Goods
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.7B
IPO Year
1993
2022

Fundamental Metrics

Financial Performance
Metric
UFPI
BLCO
Price
$90.47
$16.88
Analyst Decision
Strong Buy
Hold
Analyst Count
3
14
Target Price
$114.00
$17.31
AVG Volume (30 Days)
449.9K
488.7K
Earning Date
10-29-2025
10-29-2025
Dividend Yield
1.55%
N/A
EPS Growth
N/A
N/A
EPS
5.39
N/A
Revenue
$6,452,521,000.00
$4,976,000,000.00
Revenue This Year
N/A
$8.08
Revenue Next Year
$2.12
$5.77
P/E Ratio
$16.79
N/A
Revenue Growth
N/A
6.23
52 Week Low
$87.11
$10.45
52 Week High
$135.00
$20.71

Technical Indicators

Market Signals
Indicator
UFPI
BLCO
Relative Strength Index (RSI) 45.38 63.75
Support Level $91.04 $16.73
Resistance Level $93.98 $17.70
Average True Range (ATR) 2.01 0.53
MACD 0.21 0.16
Stochastic Oscillator 48.63 73.93

Price Performance

Historical Comparison
UFPI
BLCO

About UFPI UFP Industries Inc.

UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: